Suppr超能文献

健康成年人中高剂量丙酸杆菌 ET-3 培养物的安全性。

Safety of high doses of Propionibacterium freudenreichii ET-3 culture in healthy adult subjects.

机构信息

Meiji Dairies Corporation, 1-2-10 Shinsuna, Koto-ku, Tokyo 136-8908, Japan.

出版信息

Regul Toxicol Pharmacol. 2011 Jul;60(2):262-7. doi: 10.1016/j.yrtph.2010.12.005. Epub 2010 Dec 21.

Abstract

Propionibacterium freudenreichii ET-3 (7025) culture, a cell-free product of whey fermentation by P. freudenreichii ET-3, has been shown to promote the growth of Bifidobacteria through the action of 1,4-dihydroxy-2-naphthoic acid (DHNA). Here we report the results of two clinical studies designed to evaluate the safety of high doses of P. freudenreichii ET-3 culture medium. Study 1 had a randomized, double-blind, crossover design. Ten healthy male and four healthy female subjects received 45 tablets of either P. freudenreichii ET-3 culture medium (total daily intake of 3g solid content and 283.5μg of DHNA; active group) or placebo (unfermented product) during two 1-week supplementation periods separated by a 4-week washout period. In Study 2, 11 healthy men took four tablets of P. freudenreichii ET-3 culture medium per day (total daily intake of 0.267g solid content and 22.5μg of DHNA) for a period of 13weeks. In both studies, hematological, clinical chemistry, and urinary parameters were measured before and after each supplementation period and gastrointestinal symptoms were assessed by questionnaire. In Study 1, there were no statistically significant differences between placebo and active supplementation periods in any measured parameter and the incidence of gastrointestinal symptoms were similar between groups. In Study 2, total protein, white blood cell count, hemoglobin, and mean corpuscular hemoglobin concentration decreased significantly from baseline and mean corpuscular volume and urine pH increased from baseline. The changes in hematological parameters were deemed not to be due to P. freudenreichii ET-3 culture medium supplementation given that all parameters remained within normal ranges and were not consistent with any clinically meaningful effect.

摘要

干酪乳杆菌 ET-3(7025)培养物是干酪乳杆菌 ET-3 发酵乳清产生的无细胞产物,已被证明通过 1,4-二羟基-2-萘甲酸(DHNA)促进双歧杆菌的生长。在这里,我们报告了两项旨在评估高剂量干酪乳杆菌 ET-3 培养物培养基安全性的临床研究结果。研究 1 采用随机、双盲、交叉设计。10 名健康男性和 4 名健康女性受试者在两个 1 周的补充期内分别接受 45 片干酪乳杆菌 ET-3 培养物培养基(每日总固体摄入量为 3g,DHNA 为 283.5μg;活性组)或安慰剂(未发酵产品),每个补充期之间有 4 周的洗脱期。在研究 2 中,11 名健康男性每天服用 4 片干酪乳杆菌 ET-3 培养物培养基(每日总固体摄入量为 0.267g,DHNA 为 22.5μg),持续 13 周。在两项研究中,在每个补充期前后测量了血液学、临床化学和尿液参数,并通过问卷评估了胃肠道症状。在研究 1 中,与安慰剂相比,活性补充期在任何测量参数上均无统计学差异,且两组胃肠道症状的发生率相似。在研究 2 中,总蛋白、白细胞计数、血红蛋白和平均红细胞血红蛋白浓度从基线显著下降,平均红细胞体积和尿液 pH 从基线升高。血液学参数的变化被认为不是由于干酪乳杆菌 ET-3 培养物培养基的补充引起的,因为所有参数均在正常范围内,且与任何具有临床意义的影响不一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验